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Abstract 
We analyzed the main modalities and clinical outcomes of the early discharge outpatient model in 
autologous stem cell transplantation (EDOM-ASCT) for multiple myeloma in Italy. EDOM-ASCT 
was employed in 382 patients, for a total of 522 procedures, between 1998 and 2012. Our study 
showed high homogeneity among centers in terms of inclusion criteria, supportive care, and in 
hospital readmission criteria. Overall, readmissions during the aplastic phase occurred in 98 of 522 
transplantations (18.8%). The major extrahematological complication was neutropenic fever in 161 
cases (30.8%), which required readmission in 76 cases. The incidence of severe World Health 
Organization grade 3 to 4 mucositis was 9.6%. By univariate analysis, fever, mucositis, altered 
renal function at diagnosis, second transplantation, and transplantation performed late in the course 
of the disease were significantly correlated with readmission, whereas fever, mucositis, altered renal 
function, and timing of transplantation remained the only independent predictors by multivariate 
analysis. Overall, transplantation-related mortality was 1.0%. No center effect was observed in this 
study (P = .36). The safety and low rate of readmission of the EDOM-ASCT in myeloma trial 
suggest that this strategy could be extended to other transplantation centers if a stringent patient 
selection and appropriate management are applied. 
ntroduction 
High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) 1 and 2 
remains the standard of care for young medically fit patients with multiple myeloma (MM) 3, 
4 and 5. Recent studies also suggest that induction therapy with so-called new drugs before 
transplantation may improve clinical outcomes 6 and 7. In addition, long-term disease control can 
be achieved with a variety of post-transplantation consolidation [8] and maintenance therapies 
9 and 10. Up until now, it is, however, not clear how proteasome inhibitor and immunomodulatory 
drugs should be best incorporated in the transplantation paradigm [11]. Moreover, whether ASCT 
should be maintained as an upfront strategy or delayed until relapse is a matter of debate 12 and 13. 
Overall, the International Myeloma Working Group recommends that ASCT be invariably offered 
at some point during the disease course for eligible young patients [14]. Thus, MM remains the 
leading indication for ASCT in Europe [15]. 
Patients undergoing ASCT are usually admitted to bone marrow transplantation units on a “whole 
inpatient program,” where central venous catheter (CVC) insertion, HDC administration, 
hematopoietic progenitor cell (HPC) infusion, and supportive care during neutropenia are carried 
out in positive-pressure reverse isolation rooms, with a hospital stay of approximately 3 to 4 weeks 
15, 16 and 17. The growing demand for ASCT significantly increases waiting lists and generates 
concerns about the appropriate use of health care resources. Over the past years, a number of studies 
have investigated safety, efficacy, and potential cost advantages of outpatient programs to reduce 
hospital stays after ASCT in both hematological and nonhematological diseases [17]. The early-
discharge outpatient model (EDOM) is 1 of the most common approaches. By this model, CVC 
insertion, fluid infusion, HDC administration, and HPC infusion are carried out as inpatient care, 
whereas the management of the aplastic phase is carried out as outpatient care. Though many 
reports suggest its feasibility also in lymphoma patients after BEAM (BCNU, etoposide, cytarabine 
and melphalan conditioning) 18 and 19, stringent inclusion criteria have not yet been clearly 
defined, and policies may greatly vary especially for the management of the aplastic phase in the 
outpatient setting and for readmission criteria. The aim of this study was to retrospectively evaluate 
current policies and to analyze clinical outcomes of EDOM-ASCT in a large cohort of MM patients 
treated in Italian centers affiliated with the Gruppo Italiano per il Trapianto di Midollo Osseo 
(GITMO). 
Material and Methods 
This retrospective study was conducted through the GITMO trial office, which promotes 
independent clinical research studies in the setting of both autologous and allogeneic transplantation 
in Italy. The first questionnaire was mailed to 75 GITMO centers accredited for ASCT to evaluate 
how many had been involved in EDOM-ASCT for MM patients between 1998 and 2012. In all 
centers, eligibility to the EDOM program included availability of a caregiver on a 24-hour basis; 
housing within easy reach to the transplantation center (shorter than 1 hour drive); absence of 
multiple comorbidities as assessed by the treating physician; a baseline serum creatinine 
value < 2 mg/dL at transplantation; adequate activities of daily living, such as eating, cleaning, 
personal hygiene, and ambulation possible independently or under the supervision of a caregiver; 
and informed consent for the EDOM-ASCT program. If a given center was involved, further 
specific queries included infectious prophylaxis, supportive care, criteria for hospital readmission, 
management of febrile neutropenia, and clinical outcomes. 
Overall, 55 of 75 (73.3%) answered the first questionnaire: 49 centers performed ASCT after the 
inpatient procedure and 6 had been involved in outpatient ASCT programs according to EDOM. 
Endpoints 
Primary endpoints were to evaluate efficacy and safety of EDOM-ASCT in terms of rates of 
hospital readmission before neutrophil and platelet recoveries and early transplantation-related 
mortality (TRM). Neutrophil and platelet recoveries were defined as the first of 3 consecutive days 
of an absolute neutrophil count ≥ .5 × 109/L and the first of 3 days of a platelet count ≥ 20 × 109/L 
without transfusion support for 7 consecutive days. Early TRM was defined as mortality from any 
cause other than disease progression within 100 days from transplantation. Secondary endpoints 
were to investigate differences in center policies for patient inclusion criteria in EDOM-ASCT, 
supportive care, hospital readmission criteria, and to collect clinical data on incidence of infections, 
days of fever, hematological, and extrahematological toxicities, progression-free survival (PFS), 
and overall survival (OS). The ultimate goal was that of collecting robust information on the 
feasibility of EDOM-ASCT to help design clinical recommendations in our country. The study was 
approved by the local ethics committee of the 6 participating centers and conducted according to the 
Declaration of Helsinki. 
Statistical Analysis 
Data are summarized as median and interquartile ranges or as absolute number or percent 
frequency, as appropriate. The relationship between risk factors and the odds of hospital 
readmission before neutrophil and platelet recoveries were investigated by univariate and 
multivariate logistic regression analyses. Tested variables included gender, age, fever, World Health 
Organization (WHO) grade 3 to 4 mucositis, renal function (serum creatinine level < 2 mg/dL 
versus ≥ 2 mg/dL), number of CD34+ cells infused, granulocyte-colony stimulating factor (G-CSF) 
(filgrastim and lenograstim) versus pegfilgrastrim, first versus second transplantation, timing of 
transplantation, conditioning regimen, and disease status at transplantation. All variables correlated 
with hospital readmission with a P value of ≤ .10 were analyzed by a multiple logistic regression 
model. With this strategy, the model had adequate statistical power with at least 20 readmitted 
patients for each variable added to the final model. All P values were 2-sided at the 10% 
significance level, as suggested by McDonald et al. [20]. In both univariate and multivariate logistic 
regression models, data were expressed as odds ratio (95% confidence interval [CI] and P values). 
To ascertain the effect of repeated observations in the same patients who may have undergone more 
than 1 transplantation, a sensitivity analysis was performed by restricting the focus only on the first 
transplantation. A center-effect analysis was also carried out by comparing the point estimates and 
the 95% CI of the percentages of patients who were readmitted at the participant centers. One center 
(Potenza) was excluded by this analysis because of the low number of patients enrolled (n = 4). OS 
and progression-free survival curves were estimated by the Kaplan-Meier method. Data analysis 
was performed by SPSS for windows (version 20.0.0, IBM, Armonk, NY). 
Results 
Overall, between January 1998 and December 2012, 536 EDOM-ASCT procedures for 382 MM 
patients were performed at Italian GITMO centers. Fourteen cases (2.6%) with incomplete data set 
for the evaluation of primary endpoints of the study were excluded from the analysis, leaving 522 
eligible, representing the body of this paper. Center activities are illustrated in Figure 1 and patient 
characteristics are summarized in Table 1. 
 
 
 
 
  
  
 
 
Median age at transplantation was 58.7 (range, 27.5 to 75.4) years, and the majority of patients were 
male (66.2%). At diagnosis, serum creatinine level was < 2 mg/dL in 270 of 382 (70.7%) patients, 
and ≥ 2 mg/dL in 65 of 382 (17%) [21]. Data were missing in 47 of 382 (12.3%). Most patients 
(52.9%) received vincristine, adriamycin, and dexametasone–based induction regimens. Response 
rates by the European Society for Blood and Marrow Transplantation criteria [22] are described in 
Table 1. High-dose melphalan (HDM) 200 mg/m
2
 (84%) or 140 mg/m
2
 (16%) were employed as 
conditioning. All patients received HPC with a median dose of CD34
+
 cells of 5.0 (range, 1.2 to 
15.0) × 10
6
/kg. Discharge after the HPC infusion occurred at a median of 1 day (range, 0 to 3). 
Supportive Care 
During the aplastic phase, all patients received oral prophylaxis with ciprofloxacin at 500 mg twice 
daily or levofloxacin at 500 mg/day from day 0 until neutrophil recovery, and with acyclovir at 
800 mg twice daily from day +3 post-transplantation until approximately day +90. Pneumocystis 
Jiroveci prophylaxis with trimethoprim/sulfamethoxazole, 1 double-strength tablet 2 or 3 times 
weekly, was started after hematological recovery and continued for 3 months. Antifungal 
prophylaxis with fluconazole at 400 mg/day was started at day 0 and continued until neutrophil 
recovery only in 2 centers (Milan, San Raffaele Hospital, and Naples, Cardarelli Hospital). All 
centers except 1 used cryotherapy with ice chips for the prevention of HDM-induced oral 
mucositits. Patients started keeping ice chips in their mouths approximately 30 minutes before the 
HDM conditioning and for about 6 hours afterwards. At the University Hospital center in Ancona, 
amifostine at 750 mg/m
2
 was administered before HDM conditioning to prevent mucositis. G-CSF 
(filgrastim or lenograstim) at 5 mcg/kg/day was started at day +5 until neutrophil recovery in 217 of 
522 transplantations (42%) and single-dose pegfilgrastim at day +1 in 305 of 522 transplantations 
(58%). Red blood cell and platelet transfusions were given to maintain hemoglobin levels > 
8 mg/dL and platelet counts >10 × 10
9
/L, or in case of symptomatic anemia and/or minimal muco-
cutaneous hemorrhagic syndrome. Patients received i.v. hydration and electrolyte support as per 
institutional policy. 
Criteria for Hospital Readmission 
In all centers, criteria for readmission after early discharge included uncontrolled nausea and/or 
vomiting, diarrhea and/or severe mucositis requiring continuous fluid replacement, continuous need 
of parental nutrition or narcotic drugs, pneumonia, cardiac and/or respiratory distress, patient 
request, or any other toxicity judged unmanageable as outpatient by the medical staff. Fever without 
hemo-dynamic instability responsive to first-line antibiotics was managed on the outpatient service, 
except at the San Raffaele Hospital in Milan where patients were hospitalized. 
Management of Febrile Neutropenia 
In all centers, neutropenic fever (NF) was defined as an axillary temperature exceeding > 38.2°C on 
at least 2 consecutive occasions or a persistent temperature of equal to or greater than 38.0 C° for at 
least an hour, in the absence of any documented noninfectious cause, such as transfusion reactions 
or administration of cytotoxic drugs. Neutropenia, again, was defined as absolute neutrophil 
count < .5 × 10
9
/L or absolute neutrophil count of 1 and a predicted decline to less than .5 over the 
next 48 hours. When NF was observed, blood and catheter cultures were set up and empiric 
antibiotic therapy was promptly started. Patients received i.v. ceftriaxone at Cardarelli Hospital in 
Naples, at BMM Hospital in Reggio Calabria, and at San Carlo Hospital in Potenza, i.v. 
piperacillin-tazobactamat San Raffaele Hospital in Milan, or oral amoxicillin and clavulanic acid at 
University Hospital in Ancona. 
Transplantation Details 
Median day of discharge was day 1 (range, 0 to 3) after HPC reinfusion. Neutrophil and platelet 
engraftment occurred in all patients at a median of 10 (range, 8 to 24) and 12 days (range, 8 to 
36 days) after ASCT, respectively. Median numbers of transfused red blood cell and platelet units 
were 0 (range, 0 to 11 units) and 0 (range, 0 to 7 units), respectively (Table 2). Transfusion support 
was not statistically different in the setting of patients who required a rehospitalization (data not 
shown). Readmission until neutrophil and platelet recovery was required in 98 out of 522 
transplantations (18.8%) (Figure 1). Readmission rates did not significantly differ among the 
centers and a center effect was not observed (Figure 2). The major extrahematological complication 
was NF in 161 cases (30.8%) and was the main reason for readmission in 76 cases, whereas the 
remaining 85 cases were managed as outpatients. Median number of days of fever and antibiotic 
therapy was 3 (range, 1 to 22) and 6 (range, 0 to 25), respectively. In most cases (82%), no 
documented infections were reported. Infections documented by blood and/or urine or sputum 
cultures, or suggested by imaging studies, such as chest radiographs, and physical examination (ie, 
cellulites around the catheter exit sites) in the absence of positive cultures, were reported in 4% and 
8% of febrile episodes, respectively. In 6.2% of cases, cultures from indwelling intravenous 
catheters yielded coagulase-negative Staphylococci CVC-related infections. In the remaining 361 
procedures (69.2%), no fever was reported during neutropenia. No systemic fungal infections, either 
possible or probable, could be documented. Severe WHO 3 to 4 mucositis, according to the WHO's 
grading scale [23], was reported in 50 cases (9.6%). Other extrahematological toxicities were 
infrequent and rarely caused readmission ( Table 3). Five patients (1%) died within 100 days from 
transplantation. One patient, readmitted 4 days after discharge for NF, died on day 25 after ASCT 
for hemorrhagic stroke. Three patients died of sepsis: 1, readmitted at day 5, died of sepsis and 
respiratory failure on day 30; 1 died on day 7 with documented infection by Escheria coli, and in 
another, who died on day 15, no pathogen was identified. One additional patient developed a 
clinically documented infection (pneumonia) and died on day 12 after ASCT. In all cases, autopsy 
was not performed. 
 
  
 
Risk Factors for Readmission 
By univariate analysis, gender, age at transplantation, number of CD34
+
 infused, type of myeloid 
growth factor, conditioning regimen, and disease status at transplantation had no impact on 
readmission rate, whereas fever, mucositis, renal function (creatinine level ≥ 2 mg/dL at diagnosis), 
number of ASCT procedures (second), and timing of transplantation (ie, late in the course of the 
disease, not upfront) were significantly associated with readmission (Table 4). However, by 
multivariate analysis, only fever, mucositis, altered renal function, and timing of transplantation 
remained independent predictors. These findings were also confirmed by a sensitivity analysis 
carried out on patient characteristics at the first transplantation (see Table 4). 
 
Clinical Outcomes 
At a median follow-up of 200 months, OS and PFS were 85 months (95% CI, 76 to 93) and 
34 months (95% CI, 29 to 38), respectively. At follow-up, 20% of the patients were alive and 18% 
had not progressed (Figure 3). 
  
Discussion 
The aim of this study was to evaluate the current role of EDOM-ASCT and to analyze clinical 
outcomes on a large patient cohort in centers with long-standing experience in MM treatment. 
Despite the retrospective nature of the study, it was rather remarkable to observe that the centers 
involved shared similar patient selection criteria, antimicrobial prophylaxis, and hospital 
readmission strategies. 
The weakness of the study is the lack of a control group. A formal randomization could not be 
carried out, given that the primary endpoint was the feasibility of the EDOM-ASCT program and a 
retrospective data collection for a case-match analysis would not be possible in all centers. 
However, the data reported here, in terms of outcome, engraftment kinetics, TRM, and toxicity, are 
comparable with the main series recently reported in the literature 11, 14 and 24. Several 
manuscripts have already demonstrated that the outpatient program is feasible [17] and, in some 
studies, a clinical advantage has been shown as well as the saving of financial resources 25, 
26 and 27. Our paper, through the analysis of a remarkable number of transplantation procedures 
performed in the Italian centers, is focused on the optimization of the EDOM-ASCT. Therefore, we 
believe the only meaningful comparison (besides the description of our results) should be 
performed with similar studies published in the literature. Specifically, in our study, we showed that 
a high degree of standardized EDOM-ASCT procedures among GITMO centers is feasible, with no 
significant differences in readmission and TRM rates. Center effects may often represent an 
important bias in retrospective multicenter studies. Epidemiologists formally assess a potential 
center effect by comparing point estimates of given variables and corresponding 95% CI. A center 
effect can reasonably be excluded when CI largely overlap [28]. Large overlapping areas of CI were 
seen in our analysis, indicating that clinical outcomes were not center dependent (Figure 2). 
Overall, unlike other reports 16, 18, 29, 30, 31, 32, 33 and 34, our readmission rate, 18.8%, was 
quite low. This may be explained by a number of reasons. 
First, antimicrobial prophylaxis was routinely administered. A recent meta-analysis [35] of 109 
randomized trials in patients who developed neutropenia without fever showed that those with 
hematological malignancies and/or undergoing HPC transplantation were at higher risk of 
readmission. Moreover, a lower all-cause mortality was seen in patients on antimicrobial 
prophylaxis as compared with those who were not. Fernandez Aviles [36] reported a very low 
readmission rate, 8%, by introducing ceftriaxone prophylaxis in 50 patients with different 
hematological malignancies, although, in this study, the early discharged patients were selected in 
the light of their Eastern Cooperative Oncology Group performance status (<2). Finally, other 
reports have shown a significant reduction in mortality by adding prophylaxis with quinolones [37]. 
Second, the outpatient management of NF in most cases with oral antibiotics or once-daily i.v. 
antibiotics largely contributed to the low readmission rate, that, in turn, highly limited the risk of 
exposure to multidrug-resistant organisms commonly found on hospital wards [38]. In our 
experience, only patients with NF and/or documented infections associated with hemodynamic 
instability were hospitalized. A recently published retrospective analysis on EDOM-ASCT in 
91 MM patients by a Canadian group [18] concluded that the procedure is safe and cost effective 
when performed in a weekday clinic, though it is associated with a high readmission rate, 84%, 
especially in patients over 60 and with disease stage IIB or higher. The high rate may be explained 
by the inclusion of patients with advanced disease and different NF management. A policy similar 
to Canadian group for NF management was reported in a retrospective study by Kassar et al. [33], 
where 58% of the patients receiving ASCT required hospitalization. 
Third, our very low rate of WHO grade 3 to 4 oral mucositis, frequently associated with NF and/or 
infections 31 and 39 may likely be due to cryotherapy (administered in 371 patients) or to the use of 
amifostine (151 patients). A recent Cochrane review showed that cryotherapy (ice chips) and the 
administration of keratinocyte growth factor were of some benefit in preventing mucositis [40]. In 
our study, though not statistically significant, a lower incidence of severe mucositis was observed at 
the University Hospital of Ancona, where amifostine was routinely used a cyto-protector. However, 
it did not significantly affect the probability of readmission. Amifostine detoxifies reactive 
metabolites of platinum and alkylating agents [41] and its potential role in preventing 
extrahematological toxicity after HDM has been investigated in many studies, with contrasting 
results [42]. 
Although our experience includes patients who underwent transplantation over 10 years ago, no 
major changes in supportive care were introduced over the study period. One change was the 
introduction of long-active growth factors. Pegfilgrastim was often chosen to favor patient 
compliance, given its single dose at 6 mg s.c. rather than daily doses of either filgrastim or 
lenograstim. A systematic review comparing G-CSF and pegfilgrastim in the autologous setting, 
including a randomized trial of 80 patients, concluded that the 2 growth factors are at least equally 
effective [43]. 
Overall, the first experiences of “outpatient autografts” were reported in North America with 
readmission rates of 30% [29] and 61% [30]. Faucher et al. [16] reported a rate of 86% in the first 
randomized study comparing EDOM with standard inpatient ASCT in a cohort of 131 patients with 
nonleukemic malignant diseases. Of note, 33% of patients could not be discharged early because of 
social or psychological reasons, such as lack of a caregiver or living far away from the 
transplantation center. In another study by Gertz et al. [34], only 39% of 716 patients completed the 
procedure without readmission. Patient age (>65 years) and serum creatinine level (≥1.5 mg/dL) 
were associated with higher risk of readmission. We think that the stringent application of inclusion 
criteria, such as normal serum creatinine at the time of transplantation, the availability of a full-time 
caregiver, and living within 1-hour drive to the transplantation center, formed the basis for the low 
readmission rate reported by our centers. 
Our study was not designed to carry out a detailed cost analysis. However, several studies showed 
that outpatient models of autografting are highly cost effective, mainly because of shorter duration 
of hospitalization and reduced drug administration and laboratory costs 25, 26, 27 and 30. One 
prospective randomized study comparing an outpatient model with conventional inpatient ASCT 
[16] in patients with malignancies reported an estimated cost saving of 19%. A recent Italian study 
[19] focused on EDOM in lymphoma patients, conditioned with BEAM (BCNU, etoposide, 
cytarabine and melphalan) and given amifostine to reduce extrahematological toxicity, reported a 
very low incidence of severe mucositis and the outpatient treatment plan was successfully 
completed in two thirds of the patients. Overall, only 26% required a short readmission and this 
translated into significant cost saving. 
In conclusion, this paper showed a high degree of standardized EDOM procedures among the 
GITMO centers. The safety and low readmission rates may likely have been due to stringent 
selection criteria. Ideal candidates appeared to be those with good performance status, a full-time 
caregiver, and those who lived near the transplantation center. Moreover, NF could safely be 
managed in the outpatient service and the administration of cyto-protectors may have reduced the 
severity of mucositis and its symptoms. The detailed analysis of these clinical parameters represents 
the novelty of the paper and makes, in our opinion, this work potentially valuable for clinical 
transplantation providers. However, our results do not allow us to extensively recommend the 
EDOM-ASCT program, outside a national policy, and in centers which do not fulfill the criteria of 
an adequate skilled team and adequate logistics for the managing these patients. Future trials should 
focus on large prospective multicenter outpatient programs, which may identify patient subgroups 
who most benefit from this innovative and cost-effective approach. 
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